A transformative partnership has been forged between Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, and Eli Lilly, a…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company is embarking on a significant acquisition spree, exemplified by its recent agreement to acquire Kelonia Therapeutics…
Read More
Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal
Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as significant players in the global drug development landscape, participating…
Read More
The $1.8 Billion Telehealth Conundrum: Medvi’s Rise Amidst Regulatory Gaps, AI Deception, and the Compounded Drug Market
A recent profile by The New York Times celebrated Medvi, a burgeoning telehealth enterprise, as a testament to the transformative…
Read More
Pfizer and Innovent Biologics Announce Landmark Global Collaboration for Oncology Pipeline, Valued Up to $10.5 Billion
In a significant move poised to accelerate the development of novel cancer treatments, global pharmaceutical giant Pfizer and leading Chinese…
Read More
BioNTech’s Post-Pandemic Pivot: From €19 Billion Vaccine Bonanza to Oncology’s €16.8 Billion Bet Amidst Job Cuts and Shifting mRNA Landscape
The German biotechnology firm BioNTech, a name synonymous with the rapid development of the world’s first widely authorized mRNA COVID-19…
Read More
The Eliquis Patent Cliff: A $14.2 Billion Revenue Erosion Set to Reshape Pharmaceutical Giants
The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in…
Read More
Insilico Medicine and Eli Lilly Forge Potentially $2.75 Billion AI-Driven Drug Discovery Alliance, Signaling a New Era of Pharmaceutical Innovation
On March 29, Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, announced a landmark collaboration with…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently riding an unprecedented wave of success fueled by its GLP-1 franchise, has announced its intent…
Read More
